ospemifene 60 mg/day	placebo	endometrial cancer	23812	23929	There were no cases of endometrial cancer observed with exposure of up to 52 weeks in the ospemifene clinical trials.
ospemifene 60 mg/day	placebo	The mean (SD) increase in endometrial thickness based on TVUS	19935	20384	The mean (SD) increase in endometrial thickness based on TVUS was 0.51 (1.5) versus 0.06 (1.2) mm at 12 weeks, 0.56 (1.6) versus 0.05 (1.3) mm at 6 months, and 0.81 (1.5) versus 0.07 (1.2) mm at 12 months for participants in the ospemifene and placebo groups, respectively. The differences between participants receiving ospemifene and participants receiving placebo were statistically significant (P â‰¤ 0.001, Welch's test) at all three evaluations.
ospemifene 60 mg/day	placebo	pelvic organ prolapse	26527	26616	There were rare cases of pelvic organ prolapse in both the ospemifene and placebo groups.
ospemifene 60 mg/day	placebo	pelvic organ prolapse	26527	26763	There were rare cases of pelvic organ prolapse in both the ospemifene and placebo groups. Two women had bladder prolapse (one ospemifene participant and one placebo participant), and one ospemifene participant had a report of cystocele.
ospemifene 60 mg/day	placebo	vaginal bleeding	19213	19494	aginal bleeding or spotting was reported in 10 of 851 women (1.2%) with an intact uterus in the ospemifene 60 mg/day group (incidence rate, 2.17 per 100 patient-years) and in 5 of 543 women (0.9%) in the placebo group (incidence rate, 2.72 per 100 patient-years; P = 0.7; Table 3).
